|
GB9823103D0
(en)
*
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
EP1307201B1
(de)
|
2000-08-01 |
2004-11-24 |
Bayer HealthCare AG |
Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
|
|
EP1343506A1
(de)
*
|
2000-12-19 |
2003-09-17 |
MERCK PATENT GmbH |
Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate
|
|
DE10064105A1
(de)
|
2000-12-21 |
2002-06-27 |
Bayer Ag |
Neue Substituierte Imidazotriazinone
|
|
JP2004525890A
(ja)
*
|
2001-02-02 |
2004-08-26 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤
|
|
KR100393160B1
(ko)
*
|
2001-06-14 |
2003-07-31 |
한국과학기술연구원 |
신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
|
|
US6479493B1
(en)
|
2001-08-23 |
2002-11-12 |
Cell Pathways, Inc. |
Methods for treatment of type I diabetes
|
|
EP1436265A4
(en)
*
|
2001-09-27 |
2004-12-15 |
Smithkline Beecham Corp |
CHEMICALS
|
|
FR2842809A1
(fr)
*
|
2002-07-26 |
2004-01-30 |
Greenpharma Sas |
NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
|
|
DE10238723A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Phenyl-substituierte Pyrazolyprimidine
|
|
DE10238724A1
(de)
|
2002-08-23 |
2004-03-04 |
Bayer Ag |
Alkyl-substituierte Pyrazolpyrimidine
|
|
DE10238722A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
|
|
CN100397023C
(zh)
*
|
2003-01-04 |
2008-06-25 |
胡云北 |
黄磷废渣载热量及反应尾气发热量的回收与综合利用方法
|
|
HRP20050848A2
(en)
*
|
2003-03-04 |
2006-06-30 |
Altana Pharma Ag |
Purin-6-one-derivatives
|
|
DE102004004142A1
(de)
|
2003-05-09 |
2004-11-25 |
Bayer Healthcare Ag |
6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
|
|
DE10320785A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Healthcare Ag |
6-Arylmethyl-substituierte Pyrazolopyrimidine
|
|
US8044060B2
(en)
|
2003-05-09 |
2011-10-25 |
Boehringer Ingelheim International Gmbh |
6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
|
|
DE10328479A1
(de)
|
2003-06-25 |
2005-01-13 |
Bayer Ag |
6-Arylamino-5-cyano-4-pyrimidinone
|
|
CA2536458A1
(en)
*
|
2003-08-28 |
2005-03-10 |
Altana Pharma Ag |
Composition comprising a pulmonary surfactant and a pde2 inhibitor
|
|
DE102004001873A1
(de)
|
2004-01-14 |
2005-09-29 |
Bayer Healthcare Ag |
Cyanopyrimidinone
|
|
CN1934111A
(zh)
|
2004-02-27 |
2007-03-21 |
霍夫曼-拉罗奇有限公司 |
杂芳基稠合的吡唑并衍生物
|
|
CN101397299B
(zh)
*
|
2007-09-29 |
2011-11-16 |
温州大学 |
一种吡唑[3,4-d]嘧啶酮的合成方法
|
|
JP5498392B2
(ja)
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
KR20110063447A
(ko)
|
2008-09-08 |
2011-06-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도
|
|
PT2414363E
(pt)
|
2009-03-31 |
2014-02-26 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
|
|
AU2010232729A1
(en)
|
2009-03-31 |
2011-10-20 |
Arqule, Inc. |
Substituted indolo-pyridinone compounds
|
|
TW201118099A
(en)
*
|
2009-08-12 |
2011-06-01 |
Boehringer Ingelheim Int |
New compounds for the treatment of CNS disorders
|
|
EP2603511B1
(en)
|
2010-08-12 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
|
US20130040971A1
(en)
|
2011-02-14 |
2013-02-14 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
CA2830027C
(en)
|
2011-03-31 |
2016-04-26 |
Pfizer Inc. |
Novel bicyclic pyridinones
|
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
|
JP6043355B2
(ja)
|
2011-08-31 |
2016-12-14 |
ファイザー・インク |
ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
|
|
JO3407B1
(ar)
|
2012-05-31 |
2019-10-20 |
Eisai R&D Man Co Ltd |
مركبات رباعي هيدرو بيرازولو بيريميدين
|
|
UA110688C2
(uk)
|
2012-09-21 |
2016-01-25 |
Пфайзер Інк. |
Біциклічні піридинони
|
|
BR112015019276A2
(pt)
|
2013-02-19 |
2017-07-18 |
Pfizer |
compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
|
|
JP6425717B2
(ja)
|
2013-10-04 |
2018-11-21 |
ファイザー・インク |
ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
|
|
AP2016009465A0
(en)
|
2014-04-01 |
2016-09-30 |
Pfizer |
Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
|
|
WO2016012896A1
(en)
|
2014-07-24 |
2016-01-28 |
Pfizer Inc. |
Pyrazolopyrimidine compounds
|
|
MD20170011A2
(ro)
|
2014-08-06 |
2017-08-31 |
Pfizer Inc. |
Compuşi imidazopiridazinici
|
|
MX368391B
(es)
|
2015-02-03 |
2019-09-30 |
Pfizer |
Ciclopropabenzofuranil-piridopirazindionas novedosas.
|
|
JO3627B1
(ar)
|
2015-04-30 |
2020-08-27 |
H Lundbeck As |
إيميدازو بيرازينونات على هيئة مثبطات pde1
|
|
WO2016179059A1
(en)
*
|
2015-05-05 |
2016-11-10 |
Merck Sharp & Dohme Corp. |
Heteroaryl-pyrimidinone compounds as pde2 inhibitors
|
|
CN107787322B
(zh)
|
2015-06-17 |
2023-07-07 |
辉瑞大药厂 |
三环化合物以及它们作为磷酸二酯酶抑制剂的用途
|
|
CN113332292A
(zh)
|
2016-02-23 |
2021-09-03 |
辉瑞公司 |
6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
|
|
TWI729109B
(zh)
|
2016-04-12 |
2021-06-01 |
丹麥商Ｈ 朗德貝克公司 |
作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
|
|
PT3478679T
(pt)
|
2016-07-01 |
2021-06-30 |
Pfizer |
Derivados de 5,7-dihidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas
|
|
WO2018073251A1
(en)
*
|
2016-10-18 |
2018-04-26 |
H. Lundbeck A/S |
Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
|
|
AU2017350473A1
(en)
|
2016-10-28 |
2019-04-18 |
H. Lundbeck A/S |
Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
|
|
WO2018078042A1
(en)
|
2016-10-28 |
2018-05-03 |
H. Lundbeck A/S |
Combination treatments comprising administration of imidazopyrazinones
|
|
KR102590848B1
(ko)
|
2016-12-28 |
2023-10-19 |
다트 뉴로사이언스, 엘엘씨 |
Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
|
|
AU2018281131B2
(en)
|
2017-06-08 |
2022-01-20 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine PDE9 inhibitors
|
|
IL271290B2
(en)
|
2017-06-22 |
2023-11-01 |
Pfizer |
Dihydro-pyrrolo-pyridine derivatives
|
|
DK3717488T3
(da)
|
2017-11-27 |
2021-12-13 |
Dart Neuroscience Llc |
Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
|
|
PT3768669T
(pt)
|
2018-03-23 |
2023-04-24 |
Pfizer |
Derivados de piperazina azaspiro
|
|
USD1021287S1
(en)
*
|
2021-01-19 |
2024-04-02 |
Averia Electronics, Inc. |
Wearable light emitting module with a removable band
|
|
USD1029414S1
(en)
*
|
2021-01-19 |
2024-05-28 |
Averia Electronics, Inc. |
Wearable light emitting module with a removable band
|
|
US12144815B2
(en)
|
2021-02-23 |
2024-11-19 |
Hoth Therapeutics, Inc. |
Use of aprepitant for treating Alzheimer's disease
|
|
WO2024118524A1
(en)
|
2022-11-28 |
2024-06-06 |
Cerevel Therapeutics, Llc |
Azaindole compounds and their use as phosphodiesterase inhibitors
|
|
WO2025145091A1
(en)
|
2023-12-29 |
2025-07-03 |
Pfizer Inc. |
Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
|